Alnylam Pharmaceuticals Inc to Present HELIOS-A 18-Month Results - Conference Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Alnylam Pharmaceuticals conference call to discuss the 18-month results from the HELIOS-A Phase III study. There will be a question-and-answer session to follow. Please be advised that this call is being [recorded] at the company's request.
I would now like to turn the call over to the company.
Good morning. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today on the phone are Yvonne Greenstreet, Chief Executive Officer; Akshay Vaishnaw, President; Pushkal Garg, Chief Medical Officer; and Rena Denoncourt, Vice President, TTR Franchise lease. Also, on the line and available for Q&A is John Vest, VP of Clinical Research.
For those of you participating via conference call, the accompanying slides can be accessed by going to the Events section of the Investors page of our website, alnylam.com/events.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
